## MDT: Medtronic plc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.7% below STRENGTH zone (4.0-10.0%); PEG 3.79 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($96.31)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. Medtronic studies highlight MiniMed 780Gâ€™s cost-effectiveness**
- Source: MassDevice | 20251211T135629 | Bullish | Relevance: 100%
- Medtronic announced new data showcasing the health economic benefits of its MiniMed 780G system. Studies conducted in Japan, Hong Kong, and Australia demonstrated that the MiniMed 780G consistently improved quality of life and reduced long-term risks of diabetes-related complications, leading to meaningful cost savings that partially offset the system's upfront expenses. These findings were presented at ATTD Asia 2025, emphasizing the growing value of automated insulin delivery systems for managing type 1 diabetes.

**2. Medtronic Announces FDA Clearance of Hugo Robotic-Assisted Surgery System for Urologic Surgical Procedures**
- Source: Oncodaily | 20251210T182515 | Bullish | Relevance: 100%
- Medtronic (NYSE: MDT) has announced that its Hugo robotic-assisted surgery (RAS) system has received FDA clearance for urologic surgical procedures in the U.S. This clearance introduces a versatile robotic platform designed to expand soft-tissue robotic surgery programs and enhance access to minimally invasive care. The Hugo RAS system features a modular design, seamless integration with the Touch Surgery ecosystem for training and insights, and is supported by Medtronic's comprehensive surgical offerings.

**3. Medtronic reports first commercial use of Liberant thrombectomy system**
- Source: MassDevice | 20251210T180055 | Bullish | Relevance: 100%
- Medtronic announced the first commercial use of its Liberant thrombectomy system, designed for the removal of fresh, soft emboli or thrombi from peripheral arterial and venous systems. The system features an intelligent algorithm that adapts pulse rate for aspiration and advancements in catheter technology, aiming for precise clot removal and reduced blood loss. Medtronic plans further investments in thrombectomy, starting with the Liberant's compatibility with Excipio devices for complex cases.

**4. Westwood Holdings Group Inc. Has $11.70 Million Stake in Medtronic PLC $MDT**
- Source: MarketBeat | 20251215T135327 | Bullish | Relevance: 100%
- Westwood Holdings Group Inc. increased its stake in Medtronic PLC (NYSE:MDT) by 8.4% in the second quarter, bringing its total holdings to $11.70 million. Other institutional investors like Vanguard Group Inc., Geode Capital Management LLC, and Bank of New York Mellon Corp also boosted their positions in the medical technology company. Medtronic's stock is trading up, with a market cap of $128.02 billion, and recently announced a quarterly dividend of $0.71 per share.

**5. Reynders McVeigh Capital Management LLC Reduces Position in Medtronic PLC $MDT**
- Source: MarketBeat | 20251215T130240 | Somewhat-Bullish | Relevance: 100%
- Reynders McVeigh Capital Management LLC significantly reduced its stake in Medtronic PLC by 95.4% in the second quarter, selling 195,951 shares and retaining 9,501 shares valued at $828,000. Despite this, Medtronic reported strong Q2 earnings, exceeding analyst expectations, and received a consensus "Moderate Buy" rating with an average target price of $110.44 from analysts. The company also declared a quarterly dividend of $0.71 per share.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Barclays | $111 | $109 | +2% |
| 2025-11-20 | Truist Securiti | $110 | $103 | +7% |
| 2025-11-19 | Morgan Stanley | $117 | $107 | +9% |
| 2025-11-19 | RBC Capital | $118 | $111 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Barclays | main | Overweight |
| 2025-11-20 | Truist Securiti | main | Hold |
| 2025-11-19 | Morgan Stanley | main | Overweight |
| 2025-11-19 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($0.38M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Valuation stretched: PEG 3.8x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 9 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.79 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.4x). Analyst sentiment positive (9 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $128.1B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.79 |
| Forward P/E | 16.3 |
| Current P/E | 17.7 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.7% over 5 days). Below STRENGTH zone by 5.7pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.0%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-0.57), momentum weakening. RSI neutral at 51. OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.73% (CS: 24) | Neutral |
| RSI_14 | 51.4 | Neutral |
| MACD Histogram | -0.57 | Bearish |
| vs SMA20 | 0.987x | Below |
| vs SMA50 | 1.028x | Above |
| vs SMA200 | 1.097x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $99.87
- **Stop Loss:** $96.31 (3.6% risk)
- **Target:** $103.43 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 280
- **Position Value:** $27,963.60
- **Portfolio %:** 27.96%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*